NCT00425802
- Conditions
- Chronic Disease, Disease Attributes, Hematologic Diseases, +21 more
- Locations
-
- Memorial Sloan Kettering Cancer Center New York, United States
Clinical trial condition
Lymphoma, Large B-Cell, Diffuse
Explore clinical trials studying Lymphoma, Large B-Cell, Diffuse. Study availability and eligibility vary by location and protocol.
1,249 public trials
217 recruiting studies
Lymphoma, Large B-Cell, Diffuse trial results
NCT01562977
- Conditions
- Aggressive Lymphoma, Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, +12 more
- Locations
-
- Hospital Germans Trias i Pujol Badalona, Barcelona, Spain
- Hospital Duran i Reynals Sabadell, Barcelona, Spain
- Hospital SAS de Jerez Jerez de la Frontera, Cádiz, Spain
- Hospital Dr. Jose Molina Orosa Arrecife, Lanzarote, Spain
NCT01786135
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +22 more
- Locations
-
- University of Alabama at Birmingham Birmingham, Alabama, United States
- City of Hope National Medical Center Duarte, California, United States
- Stanford Cancer Center Stanford, California, United States
- H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States
NCT00301951
- Conditions
- Blast Crisis, Blood Protein Disorders, Bone Marrow Diseases, +55 more
- Locations
-
- UCSF Comprehensive Cancer Center San Francisco, California, United States
NCT01649856
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
- Locations
-
- EHS CAC Hospital FRANTZ FANON ZABANA BLIDA; Hematology ward Blida, Algeria
- Centre hospitalo-univerisitaire de Tizi Ouzou - Nedir Mohamed;Service d'hématologie Tizi Ouzou, Algeria
- Cemic; Haematology Buenos Aires, Argentina
- Hospital Privado de Comunidad; Oncology Mar del Plata, Argentina
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
- Locations
-
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States
Completed
Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT01481129
- Conditions
- Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
- Hopitaux de Paris Vellefaux, Paris, France
- Institut Bergonie Cancer Center Bordeaux, France
- Henri Mondor University-Hospital Center Créteil, France
- Hospital Claude Huriez Chru Lille, France
NCT00245037
- Conditions
- Amyloidosis, Blast Crisis, Blood Coagulation Disorders, +81 more
- Locations
-
- Knight Cancer Institute at Oregon Health and Science University Portland, Oregon, United States
NCT00238433
- Conditions
- Burkitt Lymphoma, Chronic Disease, DNA Virus Infections, +37 more
- Locations
-
- Knight Cancer Institute at Oregon Health and Science University Portland, Oregon, United States
NCT01926665
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
- Locations
-
- University of Texas MD Anderson Cancer Center Houston, Texas, United States